Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.70 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl 3-Phenylpropanoate SCHEMBL6734679 | 0.98 | KEAP1 (0.68) | KEAP1FFAR1TDP1CA12CA7 | |
| Methyl 3-Phenylpropanoate SCHEMBL27506579 | 0.98 | KEAP1 (0.68) | KEAP1FFAR1TDP1CA12CA7 | |
| Methyl 3-Phenylpropanoate SCHEMBL7106668 | 0.95 | KEAP1 (0.63) | KEAP1FFAR1TDP1CA12CA7 | |
| Methyl 3-Phenylpropanoate SCHEMBL168711 | 0.94 | TDP1 (0.68) | KEAP1FFAR1TDP1CA12CA7 | |
| Methyl 3-Phenylpropanoate SCHEMBL27447160 | 0.92 | TDP1 (0.66) | KEAP1FFAR1TDP1CA12CA7 | |
| Methyl 3-Phenylpropanoate SCHEMBL27315471 | 0.92 | TDP1 (0.66) | KEAP1FFAR1TDP1CA12CA7 | |
| SCHEMBL1587088 | 0.92 | FFAR1 (0.59) | KEAP1FFAR1TDP1FFAR4ALDH1A1 | |
| Methyl 3-Phenylpropanoate SCHEMBL1893702 | 0.92 | TDP1 (0.66) | KEAP1FFAR1TDP1CA12CA7 | |
| 4-Hydroxyhydrocinnamic Acid Methyl Ester SCHEMBL8402039 | 0.92 | FFAR1 (0.61) | KEAP1FFAR1TDP1CA12CA7 | |
| Methyl 3-Phenylpropanoate SCHEMBL17748824 | 0.91 | TDP1 (0.63) | KEAP1FFAR1TDP1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023199324-A1 | MIXTURE OF 3-HEXENYL ESTER ISOMERS AND USES THEREOF | AGAN AROMA & FINE CHEMICALS LTD. (IL) | 2023-10-19 | — | — | WO | disclosed |
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-7901894-B2 | Kinase inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-03-08 | — | — | US | disclosed |
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-02-03 | — | — | US | disclosed |
| EP-1147214-B1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | UNIV NEW YORK STATE RES FOUND (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7838542-B2 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-7772216-B2 | Protein kinase and phosphatase inhibitors and methods for designing them | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2038254-A2 | BICYCLIC COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | Kinex Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7427608-B2 | Protection against and treatment of hearing loss | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1444204-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040019015-A1 | Protection against and treatment of hearing loss | HEALTH RESEARCH, INC. (ROSWELL PARK DIVISION) | 2004-01-29 | — | — | US | disclosed |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2003-09-04 | — | — | US | disclosed |
| WO-2003035621-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-1147214-A1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042213-A1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0420532-B1 | Process for producing 3,4-dihydrocoumarin derivatives | SUMITOMO CHEMICAL CO (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5237075-A | Process for producing 3,4-dihydrocoumarin derivatives | SUMITOMO CHEMICAL CO., LTD. (JP) | 1993-08-17 | — | — | US | disclosed |
| EP-0551019-A1 | Catalytic process of producing coumarin and derivatives thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-07-14 | — | — | EP | disclosed |
| EP-0420532-A2 | Process for producing 3,4-dihydrocoumarin derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | PTPN5, PTPN2, PTPN4 | KEAP1 2979/4885FFAR1 2836/4885TDP1 1504/4885 |
| US-20040019015-A1 | Protection against and treatment of hearing loss | NTRK2, AIFM2, AIFM1 | KEAP1 284/4885FFAR1 4659/4885TDP1 627/4885 |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | MAP3K20, MAP3K6, MAP3K2 | KEAP1 1060/4885FFAR1 3715/4885TDP1 1772/4885 |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | PTPN5, PTPN2, PTPN6 | KEAP1 3085/4885FFAR1 2638/4885TDP1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.